This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
Cryoport, Inc. ("Company"), the world's leading cryogenic logistics company, today announced that one of the world's foremost contract manufacturers to the biopharma industry ("the Client") will convert its fleet of liquid nitrogen dewars supporting shipping of its contract manufacturing biologics and cell therapy businesses to Cryoport's industry-leading and comprehensive logistics solutions. Cryoport solutions include comprehensive order entry information, customs management, innovative real time tracking, intervention where necessary, advanced information technology, and archiving scientific and regulatory information.
By adopting this program, the Client will have access to Cryoport's Cryoport Express® Shippers, advanced SmartPak II(TM) Condition Monitoring Systems and industry leading logistics management to ship temperature-controlled materials to and from its manufacturing facilities in the United States, the European Union and Asia. The SmartPak II(TM) Condition Monitoring System works seamlessly with Cryoport's Cryoportal(TM) logistics management platform to provide real-time conditions and location visibility. Cryoport's unique solutions provide automated alerts regarding temperature deviations, transit time deviations, LN(2) hold time remaining, battery power levels and shipper orientation.
The Client is an established supplier to the pharmaceutical industry with global manufacturing and development expertise, advanced technologies and high-quality products. It has multiple manufacturing and R&D centers worldwide. The company provides product development services to the pharmaceutical and biologic industries, including custom manufacturing of biopharmaceuticals and services for the bioscience sector.
As the world's leading cryogenic logistics company, Cryoport supports many ground breaking and industry leading companies and organizations including Fred Hutchinson Cancer Research Center, MD Anderson Cancer Center, ImmunoCellular Therapeutics, Kite Pharma, WuXi AppTec, Capricor, StemCell Technologies, Yancey Farms, Zoetis, Smithsonian Institution, Rockefeller University, University of Pennsylvania, etc.
Jerrell Shelton, CEO of Cryoport, Inc., stated, "It is indeed an honor to continue to have such well-respected multinational companies select Cryoport as their logistics partner. We have an offering that suits the needs of large and small companies in the life sciences industry and this latest customer win is a great example of how our solutions provide the best options for companies needing support in the vital area of temperature controlled logistics for the life sciences. Our Cryoport Express ® Shippers, in combination with our Cryoportal(TM) management platform, the SmartPak II(TM) Condition Monitoring System, and our most excellent Client Care Team provide our new Client with comprehensive solutions specifically developed to limit product degradation during transit -- anywhere in the world"
